Chronic obstructive pulmonary disease is a lung condition characterized by persistent airflow limitation and is associated with several extrapulmonary manifestations and comorbidities. Cardiovascular diseases are among the most frequent comorbid conditions affecting patients with chronic obstructive pulmonary disease and contribute significantly to the severity, morbidity, and mortality. Chronic obstructive pulmonary disease shares common risk factors with cardiovascular diseases (i.e. smoking, low socioeconomic class, sedentary lifestyle). However, alternative mechanisms are involved in the pathogenesis of cardiovascular disease that may have a role in driving the increased cardiovascular risk associated with chronic obstructive pulmonary disease. In this manuscript we will discuss the potential mechanisms that link chronic obstructive pulmonary disease to an increased risk of cardiovascular disease. (BRN Rev. 2016;2:69-81) Corresponding author: William MacNee, w.macnee@ed.ac.uk 
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is a lung disease that is characterized by persistent airflow limitation that is usually progressive and associated with an enhanced chronic inflammatory response in the airways and the lung to noxious particles or gases 1 . Like many chronic inflammatory conditions, COPD is associated with extrapulmonary effects and comorbidities that contribute to the overall severity in individual patients. Among these there is an association between COPD and cardiovascular disease (CVD). Cardiovascular disease contributes significantly to the morbidity and mortality in COPD 2 .
The mechanism responsible for the increased risk of CVD in patients with COPD is not known; however, a number of mechanisms have been proposed, which will be discussed in this review.
EPIDEMIOLOGIC LINK BETWEEN COPD AND CARDIOVASCULAR DISEASE
In the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study there was an increased prevalence of cardiovascular comorbidities, including hypertension, angina, stroke, heart failure, and arrhythmias in patients with COPD compared to smokers and non-smokers with normal lung function 3 . In a large cohort of COPD patients from the Veterans Administration service, coronary artery disease (CAD) had a prevalence of 33.6% compared with 27 .1% in a matched cohort without COPD 4 . Population studies have shown that airflow limitation as measured by forced expiratory volume in 1 second (FEV 1 ) is a predictor of cardiovascular risk 5 . Even a moderate reduction in FEV 1 increases the risk of morbidity and death and increases cardiovascular events by two to three times 6, 7 . In the Lung Health Study in 5,887 patients with COPD with mild-to-moderate airflow limitation, for every 10% decrease in FEV 1 there was an increase of 28% in fatal and 20% in nonfatal coronary events 8 . In the National Health Interview Survey of 18,342 individuals over 40 years of age, the presence of COPD increased the odds of CVD by 2.7 7 . The Atherosclerosis Risk in Communities (ARIC) population study with 14 years follow-up showed an increase in prevalence of cardiovascular events in individuals with COPD in comparison to controls 9 .
However, the relative risks were markedly reduced after adjusting for covariates that included traditional cardiovascular risk factors in contrast to the majority of studies of cardiovascular risk in COPD, suggesting that this comorbid condition may be mediated by the high prevalence of traditional risk factors in COPD.
If the enhanced development of atheroma in COPD is a cause of increased cardiovascular risk in COPD, we would expect that patients with COPD would have increased atherosclerotic plaque burden, and indeed carotid intimal thickening as a measure of atherosclerotic plaque burden is increased in smokers with airflow limitation compared to those without 10 (Fig. 1) . In another study of patients with established vascular disease, COPD was associated with increased carotid intimal thickening in those with COPD and was associated with cardiovascular and all-cause mortality 11 . 
NS: not significant
Systemic arterial stiffness is another measure of cardiovascular risk and is increased in COPD patients compared to non-smokers and smokers with normal lung function, after correction for smoking history 12 (Fig. 2 A) . Arterial stiffness is associated with emphysema, independent of other factors such as smoking history 13 (Fig. 2 B) , suggesting that COPD constitutes an independent risk for CAD.
Cardiovascular disease is a leading cause of death in patients with COPD. In the Lung Health Study, 25% of COPD subjects died of a cardiovascular event 8 . In the ECLIPSE cohort, the probability of survival was markedly reduced in those patients with cardiovascular comorbidities 3 . In the same cohort, the extent of coronary artery calcification as a measure of the extent of CAD was significantly higher in COPD patients compared with smokers or non-smokers without COPD, and was an independent risk factor for mortality (Fig. 3) 14 .
Thus, a range of population studies and studies in patients with COPD indicate that COPD is an important risk factor for ischaemic heart disease and death from a cardiovascular cause. . A cohort of smokers who had moderate-to-high levels of physical activity had lower lung function decline, and consequently a lower risk of developing COPD, than in those who were inactive 19 . Physical activity is markedly reduced in patients with
POTENTIAL MECHANISMS

Shared risk factors
COPD shares common risk factors with CAD. Cigarette smoking is the most important established risk factor for COPD and is also a risk factor for CAD. Since smoking and COPD are inextricably linked, it is difficult, in a COPD population, to show that the increased risk of CVD in COPD is due to COPD itself. It is likely that cigarette smoke contributes to the development of CVD in COPD. However, carotid intimal medial thickness, a measure of atherosclerotic plaque burden, is increased in smokers with chronic airflow limitation compared to matched smokers and non-smokers without airflow limitation 10 . In addition, arterial stiffness, a risk factor for cardiovascular events, is also increased in COPD patients independent of smoking history 13 . This suggests that smokers with COPD have evidence of increased atherosclerotic burden independent of cigarette smoking.
Other risk factors for ischaemic heart disease are common in COPD patients, such as an increased prevalence of diabetes and hypertension 15 . Since hyperlipidaemia is not more prevalent in COPD patients, the increased cardiovascular risk in COPD is less likely to be attributed to an atherogenic lipid pattern 16 .
Several features of COPD can be associated with increased cardiovascular risk, such as gas exchange abnormalities, polycythaemia, systemic inflammation, lung hyperinflation, and a sedentary lifestyle.
Physical inactivity is a known risk factor for CVD 17 . Inactivity is also a risk factor for the COPD and is an independent predictor of risk of hospitalizations and mortality in COPD 19 .
Regular physical activity has been associated with an improvement in endothelial function, has anti-inflammatory effect, reduces body weight, fat mass and circulating lipids, the metabolic cost of activities, and improves insulin sensitivity and angiogenesis and increases the resistance of myocardial cells to ischemia 19 .
Reduced physical activity levels, a feature of COPD, may be one factor accounting for the higher risk of cardiovascular morbidity in patients with COPD.
Systemic inflammation
COPD is associated not only with pulmonary but also systemic inflammation. A systematic review showed that a range of systemic inflammatory markers, including blood leukocyte count, C reactive protein (CRP), interleukin-6 (IL-6), and fibrinogen, were elevated in COPD patients compared with smoking controls 20 . Systemic inflammation may contribute to the extrapulmonary features associated with COPD such as an increased risk of CVD 21 .
However, recent studies indicate that sustained systemic inflammation occurs in only some COPD patients 22 , and its relationship to the development of CVD has not been fully established, although patients with COPD and comorbid CVD tend to have higher systemic levels of biomarkers, such as IL-6 and fibrinogen, than those without this comorbidity 23 .
COPD is associated with exacerbations during which systemic inflammation is often further enhanced 24 . As part of this inflammatory response, platelet-monocyte aggregates increase during exacerbations of COPD 25 and may represent one mechanism by which inflammation may enhance cardiovascular risk in COPD. Studies also indicate that an elevated troponin T during exacerbations of COPD, indicating cardiac injury, is associated with an increased risk of death following exacerbation 26 . It is well established that markers of systemic inflammation predict future cardiovascular events 27 .
Most serum proteins are secreted by non-pulmonary organs, such as the liver and the bone marrow, and therefore have only an indirect link to the lung inflammation in COPD. However, pulmonary and activation-regulated chemokine (PARC)/CC-chemokine ligand-18 (CCL-18) is a protein that is constitutively expressed by monocytes/macrophages and dendritic cells and is secreted predominantly in the lungs and is present in blood at higher levels in COPD than in smokers or non-smokers without COPD 28 . Although the biological role of PARC/CCL-18 is not known, serum levels are elevated in acute coronary syndromes 29 . In addition, elevated PARC/CCL-18 levels were associated with increased risk of cardiovascular hospitalization and mortality in COPD patients 28 .
The mechanisms by which systemic inflammation plays a role in the pathogenesis of CVD are complex. However, inflammation is an important aspect of atherosclerotic plaque initiation, development, and rupture 30 . Atherosclerosis starts with injury to the vascular endothelium due to a variety of factors, including systemic inflammation and oxidative stress increasing endothelial permeability enabling lipoproteins to enter the intima. Systemic oxidative stress and inflammation and modified lipoproteins induce cytokine production and increase the expression of cell adhesion molecules, such as inter-cellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion protein-1 (VCAM-1), on the vascular endothelium, allowing circulating leukocytes to adhere to damaged endothelium. Chemotaxins direct migration of these leukocytes to the vascular intima. There is increased expression of scavenger receptors on monocytes/macrophages that ingest modified lipid lipoprotein particles, promoting the development of foam cells. This is followed by the proliferation of vascular smooth muscle cells that migrate from the media into the intima. These muscle cells produce extracellular matrix, which accumulates in the plaque with the formation of fibro-fatty lesions, resulting in vessel wall fibrosis and consequent smooth muscle cell death. Calcification may occur, resulting in a plaque with a fibrous cap surrounding a lipid-rich core.
A number of cells and molecules can both promote and amplify this inflammatory process. Activated T-lymphocytes and macrophages can stimulate the release of cytokines, resulting in endothelial activation. Cytokines such as IL-1, IL-6, and tumour necrosis factor alpha (TNF-α) can facilitate the deposition of components of atheromatous plaque formation. C-reactive protein (CRP) produced by hepatocytes stimulated by IL-6 is released after vascular damage; it can upregulate other inflammatory cytokines, activate complement, and promote the uptake of low-density lipoproteins by macrophages. C-reactive protein also interacts with endothelial cells to stimulate the production of IL-6 and endothelin-1 31 . It may adversely affect vasomotor endothelial function through the inhibition of endothelial nitric oxide synthase and consequently the production of nitric oxide (NO).
Endothelial fibrinolysis is also impaired by CRP, which induces the production plasminogen activator inhibitor-1 (PAI-1), an inhibitor of tissue plasminogen activator 32 . A number of other inflammatory biomarkers have also been implicated in plaque formation, such as IL-6, IL-8, and fibrinogen 33 .
Direct evidence of inflammation has been shown in the vascular wall of the aorta on 18 F fludeoxyglucose (FDG) positron emission tomography imaging and has been shown to be increased in COPD patients compared with smoking controls 34 .
Plasma fibrinogen levels are higher in stable COPD patients than in healthy subjects, independent of current smoking 35 . This increase in procoagulant activity in COPD may result from inflammation, triggering coagulation by promoting tissue-factor gene expression in endothelial cells. There is a direct relationship between plasma fibrinogen and the incidence of cardiovascular events in the general population, and higher plasma fibrinogen levels increases the risk of mortality in subjects with COPD. Fibrinogen levels rise further during COPD exacerbation 36 , when there is increased risk of cardiovascular events 37 .
A number of studies have investigated the expression of cell-surface receptors in COPD. Expression of P-selectin glycoprotein ligand-1 (PSGL-1) has been shown to be greater on the surface of leukocytes from patients with COPD compared with both smoking and non-smoking controls 38 . The PSGL-1 on leukocytes binds to p-selectin on activated platelets, forming platelet-monocyte aggregates. P-selectin is also expressed on endothelial cells, facilitating leukocyte adhesion to the endothelium. Elevated soluble p-selectin levels are associated with increased risk of cardiovascular events in apparently healthy individuals 39 . Soluble p-selectin levels are higher in COPD patients compared to controls 40 . Platelet-monocyte aggregation, a sensitive and specific measure of platelet activation, is increased in healthy smokers and has been implicated as a mechanism by which smoking increases cardiovascular risk 41 . Platelet-monocyte aggregation is also increased in ex-smokers with stable COPD compared to ex-smoking controls and is further increased during exacerbations of COPD 25 . Thus, interactions between inflammatory cells and platelets may play a role in the pathogenesis of vascular events in COPD. Since inflammation is integrally involved in the initiation and progression of CVD 42 , systemic inflammation, a feature of COPD, may be a mechanism linking COPD to an increased risk of CVD. However, the association between systemic inflammation and poor outcome should be interpreted with caution. Descriptive studies show associations, but do not prove causality. Moreover, the systemic inflammatory response in COPD is complex and may only be a relevant pathogenic mechanism in a portion of patients.
OXIDATIVE STRESS
Both pulmonary and systemic oxidative stress are present in COPD patients and are thought to be involved in the pathogenesis of this condition and its comorbidities 43 . Systemic oxidative stress is also thought to be involved in the pathogenesis of CAD 44 . Several traditional risk factors, including hypertension, hypercholesterolaemia, smoking, and diabetes, are associated with increased production of reactive oxygen species (ROS) from smooth muscle cells and the vascular endothelium. The ROS are involved in the pathogenesis of atherosclerosis by a number of mechanisms: lipid oxidation, upregulation of cell adhesion molecules, apoptosis of endothelium, proliferation of vascular smooth muscle, activation of matrix metalloproteinases, and altered vasomotor activity 45 .
There are no studies that have specifically addressed the involvement of increased oxidative stress in COPD in the development of CVD. Measurement of ROS is problematic and addressing the issue of increased oxidative stress in COPD and its effect on cardiovascular risk is therefore difficult. However, studies suggest that inhaled particulate matter may result in endothelial dysfunction as a result of the effects of ROS on NO and similar mechanisms may be present in COPD 44 .
Physiological stresses
COPD patients are subject to hypoxia, either intermittent hypoxia during exercise or exacerbations sustained in patients with severe disease. Hypoxia can influence atherogenesis by increasing systemic inflammation and oxidative stress, upregulating cell adhesion molecules, and inducing haemodynamic stress [46] [47] [48] . Hypoxia can also stimulate increased foam cell production 7, 46 , upregulate the cellular adhesion molecules ICAM-1 and P-selectin in endothelial cells 47 , increase CRP production 48 , and induce oxidative stress.
Hypoxia also induces haemodynamic stress 49 . In normal subjects, a hypoxic challenge increases heart rate and cardiac index. Hypoxia also reduces renal blood flow and activates the renin-angiotensin system, with consequent increased peripheral vasoconstriction and oxidative stress 50 .
Sympathetic nervous system activation is associated with increased risk of CVD 51 . COPD is associated with sympathetic nervous system activation 52 , which may contribute to the development of CVD. A high resting heart rate, a feature of sympathetic nervous system activation, is an independent risk factor for cardiovascular morbidity and mortality in the general population, and resting tachycardia is common in COPD 52 . COPD is also associated with reduced heart rate variability 53 , a marker of abnormal cardiac autonomic regulation, which is a predictor of mortality in the elderly 54 .
Abnormal vascular structure and function
Abnormalities of the vascular wall structure and function are known to predispose to and predict future cardiovascular events and mortality. Several studies have used flow-mediated dilation as a measure of endothelial function in COPD. This technique uses ultrasound to assess the dilation of the brachial artery following arterial occlusion 55 . The subsequent reactive hyperaemia is primarily dependent on the release of the vasodilator NO from the endothelium. Impaired flow-mediated dilation is associated with both the severity of airflow limitation and emphysema in a population of former smokers with and without COPD 56 . It has been shown in patients with COPD compared to healthy controls and smokers with normal lung function 57 , and was associated with the level of impaired lung function and with markers of systemic inflammation including CRP, suggesting that systemic inflammation may play a role in vascular dysfunction in COPD.
Arterial stiffness can be assessed as the carotid-femoral pulse wave velocity (PWV), which measures the speed of the pulse wave across the aorta 58 . Aortic PWV is predictive of cardiovascular events in healthy individuals and is associated with mortality in patients with ischemic heart disease 59 . Arterial stiffness is influenced by the structural components of the vessel wall, including the endothelium, the vascular smooth muscle, and the extracellular matrix. There is a relationship between reduced lung function and increased PWV in men free from CVD that is independent of traditional risk factors for CVD such as smoking, hypertension, and hyperlipidaemia 60 . In COPD patients, arterial stiffness is increased compared with matched controls, and was associated with the level of airflow limitation and blood IL-6 and CRP levels 61, 62 , suggesting a role for systemic inflammation in the pathogenesis of arterial stiffness in COPD. In a larger cohort of patients with COPD, an independent association between FEV 1 and PWV was confirmed and close association between computed tomography (CT)-measured emphysema severity and arterial stiffness was found after adjusting for traditional risk factors 13 .
To determine the mechanism for the increased arterial stiffness in COPD, a case-control study measured endothelial function and arterial stiffness in patients with COPD and controls well matched for age and cigarette smoke exposure 12 . This study confirmed an increased arterial stiffness in patients with COPD, but found no differences between the groups in two measures of endothelial function: vasomotion (in the resistance vessels of the forearm vascular bed) and the release of the endogenous fibrinolytic tissue plasminogen activator. From these studies it was suggested that the increased arterial stiffness in COPD may be due to abnormalities of extracellular matrix in the arterial wall as a result of elastin degradation that may occur in the lungs, resulting in emphysema, and in the vasculature, giving rise to increased arterial stiffness. Support for this hypothesis comes from a study showing an association between skin wrinkling, suggestive of increased systemic elastin degradation and emphysema severity in a COPD cohort 63 and from a study showing increased cutaneous elastin degradation in patients with COPD that was associated with both emphysema severity and increased arterial stiffness 64 . Moreover, plasma desmosine, a marker of systemic elastin degradation, is associated with the presence of CVD and has a positive correlation with arterial stiffness in a cohort of COPD patients 65 .
As the elastin in the walls of large vessels is degraded, calcification occurs (medial elastocalcinosis), which is a feature of normal ageing 66 . Emphysema severity as measured by CT scanning has been shown to correlate with thoracic and distal aortic calcification, both in healthy individuals and in those with COPD 67 . Moreover, aortic calcification has been related to measures of arterial stiffness and to mortality in COPD patients 68 .
Protease/antiprotease imbalance
Protease/antiprotease imbalance is thought to be an important pathogenic mechanism in both COPD and CVD.
Matrix metalloproteinases (MMP) are thought to be important in the pathogenesis of COPD. Expression of MMP-2 protein is increased in peripheral lung tissue and in alveolar macrophages, and its activity was increased in the sputum of COPD patients in comparison with healthy smokers and non-smokers 69, 70 . MMP-2 has also been linked with the development of CAD. MMP-2 is increased in atherosclerotic plaques in the aorta 71 and in coronary atherosclerotic lesions 72 and increased serum MMP-2 is also associated with increased arterial stiffness 73 .
Matrix metalloproteinase-9 has also been implicated in the pathogenesis of emphysema. The MMP-9 promoter polymorphisms are associated with upper zone predominant pulmonary emphysema 74 . Peripheral blood monocytes from COPD patients show enhanced release of MMP-9 compared with cells from controls 75 and higher circulating levels of MMP-9 have been shown in COPD patients 76 . MMP-9 has also been implicated in the development of arterial stiffness and atherosclerosis. Atherosclerotic plaques demonstrate increased concentrations of MMP-9 77 . Circulating MMP-9 levels are associated with increased arterial stiffness 73 . In addition, polymorphisms in the MMP-9 gene, which result in higher MMP-9 mRNA expression, protein levels, and MMP-9 activity in vascular tissue, are associated with arterial stiffness 73 .
Upregulation of cutaneous MMP-2 and -9 gene expression has been shown to correlate with skin elastin degradation, which in turn correlates with arterial stiffness 64 . Thus, upregulation of MMPs may also occur in the arteries of COPD patients, resulting in elastin degradation and increased arterial stiffness, and locally increased MMPs in the lungs may result in emphysema, providing a mechanistic link between emphysema and arterial stiffness and hence cardiovascular risk in COPD.
Ageing
Ageing is among the greatest known risk factors for most chronic diseases. Airspace enlargement and loss of lung elastic recoil (as in emphysema), increased arterial stiffness, and vascular calcification are all features seen in normal ageing 78, 79 . Similarities between features of COPD and the ageing lung suggest that COPD may be a condition related to accelerated ageing 80 . Shorter telomeres, a marker of ageing, occur in peripheral blood leukocytes from COPD patients compared with control subjects 81 . Shorter telomeres are also present in cells from emphysematous lungs compared with control lungs 82 . When telomere length reaches a critical value, cell-cycle arrest (senescence) occurs. Cell senescence is the cellular equivalent of ageing. Senescent cells express a different gene profile, including the cell cycle control kinase inhibitors p53, p21, and p16, which are increased in emphysematous lungs compared with the lungs of smokers without COPD 82 . Cellular senescence can contribute to the pathogenesis of COPD and emphysema by increasing epithelial and endothelial cell apoptosis, which results in loss of cells in the alveolar walls 83, 84 . There is also a relationship between the extent of cellular senescence and the severity of inflammation in emphysema 85 . Metabolic nicotinamide adenine nucleotide-dependent histone/protein deacetylases (sirtuins) have an important role in senescence and ageing 86 . Sirtuin-1 (SIRT-1) has been shown to be reduced in lung cells from COPD patients as a result of post-translational oxidative modification of the molecule and increased acetylation and enhanced inflammatory responses to cigarette smoke 87 .
Accelerated ageing mechanisms are also implicated in the pathogenesis of atherosclerosis.
Endothelial cell senescence is thought to have endothelial dysfunction and atherogenesis 88 . Shortened leukocyte telomere length has been associated with increased arterial stiffness 89 and is a predictor of future coronary heart disease events 90 . Furthermore SIRT-1 plays a critical role in endothelial cell homeostasis and may protect against vascular senescence, dysfunction, and atherosclerosis 91 . Thus, mechanisms leading to accelerated ageing in the lungs and in the vasculature may provide a mechanistic link between COPD and vascular dysfunction.
CONCLUSIONS
A number of putative mechanisms have been proposed that link coronary heart disease and COPD (Fig. 4) . Although COPD is associated with a number of measures of cardiovascular risk and with mediators of cardiovascular disease, atherosclerosis, and thrombosis, it is as yet unclear whether these markers play a specific role in the pathogenesis or are epiphenomena. Although we are closer to uncovering the causative mechanisms for cardiovascular disease in COPD, more work is required to elucidate these, which should provide novel targets for treatment of both the lung and cardiovascular manifestations of COPD.
